13 March 2020 | News
Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ in Greater China and South Korea
Image credit- shuttershock.com
US based Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, has acquired an exclusive license for the commercialization and development of XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.
XIPERE is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside’s proprietary SCS Microinjector™ that is being investigated as a targeted treatment of macular edema associated with uveitis.
Under the terms of the agreement, Clearside may receive up to a total of $35.5 million in development and sales milestones. This amount includes a $4.0 million upfront payment plus additional milestone payments for the achievement of specified events prior to and including receipt of approval of XIPERE in the United States. Clearside also will be entitled to receive tiered royalties of 10% to 12% based on annual net sales of XIPERE in Greater China and South Korea. Arctic Vision may pursue development and commercialization of XIPERE for additional ophthalmic indications in Greater China and South Korea, with consent from Clearside.